CBD (Cannabidiol) has become one of the most studied and popularly consumed dietary supplements in recent years.
I compiled an article a while back called The Evidence-Based Health Benefits Of Cannabidiol (CBD) sharing some of the latest scientific research on the potential health benefits of CBD (Cannabidiol).
However, there has been considerable research and systematic reviews released in the meantime, so I thought it would be a good idea to do a second part to this series and continue share some of the latest studies on the health benefits of CBD.
Things are looking very promising for CBD and cannabis derived medicines in general, as they continue to gain popularity and acceptance both in the medical field and validated by continued research from the scientific community.
Much like THC, CBD(Cannabidiol) continues to be considered one of the most “medicinal” cannabinoids of the Cannabis Sativa plant and has a number of benefits including anti-inflammatory, anxiolytic and neuroprotective properties.
A Systematic Review Of Cannabidiols (CBD) Health Benefits
A systematic review published in January 2020 evaluated the therapeutic role of Cannabidiol in psychiatric disorders.
The systematic review concluded:
CBD and CBD-containing compounds such as nabiximols were helpful in alleviating symptoms of cannabis-related disorders, schizophrenia, social anxiety disorder, and comorbidities of ASD, and ADHD with moderate recommendation.
However, there is weaker evidence for insomnia, anxiety, bipolar disorder, posttraumatic stress disorder, and Tourette syndrome. The evidence for the use of CBD and CBD-containing compounds for psychiatric disorders needs to be explored in future studies, especially large-scale and well-designed RCTs. 
“CBD and CBD-containing compounds such as nabiximols were helpful in alleviating psychotic symptoms and cognitive impairment in patients with a variety of conditions, and several studies provided evidence of effectiveness in the treatment of cannabis withdrawal and moderate to severe cannabis use disorder with Grade B recommendation.
There is Grade B recommendation supporting the use of CBD for the treatment of schizophrenia, social anxiety disorder and autism spectrum disorder (ASD), and attention deficit hyperactivity disorder (ADHD).
Grade C recommendation exists for insomnia, anxiety, bipolar disorder, posttraumatic stress disorder, and Tourette syndrome.
The information in this article has not been evaluated by the FDA and should not be used to diagnose, cure or treat any disease, implied or otherwise.